Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06695130 · ClinicalTrials.gov registry record · Phase 1
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
A Phase 1 study of Influenza Immunization and COVID-19 Immunization, sponsored by Sanofi.
- Active
- Registry status
- Phase 1
- Development phase
- 980
- Enrollment target
- 12
- Study locations
NCT06695130 is a Phase 1 study of Influenza Immunization and COVID-19 Immunization that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 980 participants, above the 449-participant average among 3 other Influenza Immunization trials with a reported enrollment target (118% higher). The trial reports 12 study locations across 10 states.
The verdict
NCT06695130, a Phase 1 study of Influenza Immunization and COVID-19 Immunization, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 980 participants
- Enrollment target
- 12
- Study locations
Study Summary
Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of recombinant influenza vaccine (RIV) + adjuvanted recombinant COVID-19 vaccine (rC19) vaccine comprised of RIV combined with different recombinant Spike (rS) antigen levels of rC19 compared to RIV alone, rC19 (dose 1) alone, and RIV and rC19 (dose 1) (coadministered in opposite arms). Placebo will be coadministered in the RIV alone, rC19 (dose 1) alone, and RIV + rC19 study groups to control for the number of injections and to maintain observer blinding. Thus, each participant will receive two injections at enrollment, one in each deltoid muscle. Study details include: * The study duration will be approximately 12 months * Study intervention will be administered via a single intramuscular (IM) injection into the right and left deltoid muscles on Day(D) 01 * Dose escalation with sequential enrollment (sentinel cohort followed by main cohort for a given dose) * The visit frequency for participants will be D01 and D30, and D09-D366 (telephone call) Number of Participants: Approximately 980 participants are expected to be randomized.
Conditions Studied
Interventions
- BIOLOGICAL rC19 (dose 1)
- BIOLOGICAL RIV (recombinant influenza vaccine)
- BIOLOGICAL RIV + rC19 (dose 1)
- BIOLOGICAL RIV + rC19 (dose 2)
- BIOLOGICAL RIV + rC19 (dose 3)
Study Locations (12)
California
- Synexus Clinical Research US, Inc. - Cerritos- Site Number : 8400002 - Cerritos
- Synexus Clinical Research US - Vista- Site Number : 8400010 - Vista
Florida
- Optimal Research - Florida- Site Number : 8400006 - Melbourne
- Synexus Clinical Research US - Orlando- Site Number : 8400007 - Orlando
Arizona
- Central Phoenix Medical Clinic- Site Number : 8400009 - Phoenix
Illinois
- Optimal Research - Illinois- Site Number : 8400008 - Peoria
Indiana
- Synexus Clinical Research US - Evansville- Site Number : 8400004 - Evansville
Massachusetts
- Walgreens Clinical Trials-Malden- Site Number : 8400012 - Malden
Minnesota
- Synexus Clinical Research US - Minneapolis- Site Number : 8400011 - Richfield
Nevada
- Synexus-Las Vegas- Site Number : 8400005 - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 980 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2026-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06695130
The ClinicalTrials.gov registry entry for NCT06695130 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 980 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 449-participant average among 3 other Influenza Immunization trials with a reported enrollment target (118% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Influenza Immunization appearing as the primary indexed condition, and to 5 interventions - of which rC19 (dose 1) is the first listed.
NCT06695130 reports 12 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06695130 about?
NCT06695130 is a clinical study titled "Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older". Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of recombinant influenza...
What is the current status of trial NCT06695130?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 980 participants. The study started on 2024-11-18. Estimated completion is 2026-04-03.
What conditions does trial NCT06695130 study?
This clinical trial studies the following conditions: Influenza Immunization, COVID-19 Immunization.
What interventions are being tested in trial NCT06695130?
The interventions under investigation include: rC19 (dose 1) (BIOLOGICAL), RIV (recombinant influenza vaccine) (BIOLOGICAL), RIV + rC19 (dose 1) (BIOLOGICAL), RIV + rC19 (dose 2) (BIOLOGICAL), RIV + rC19 (dose 3) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06695130?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06695130 being conducted?
This trial has 12 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza Immunization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older
ACTIVE NOT RECRUITING · Phase 1
-
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.